Showing results (241-250 of 438) with videos related to

Sort By:
Pageof 44
JAMA Oncology|November 27, 2018
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical TrialChiara Cremolini, Daniele Rossini, Emanuela Dell'Aquila, et al.
The Oncologist|March 31, 2025
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2Cathy Eng, Arvind Dasari, Sara Lonardi, et al.
The Lancet. Oncology|April 17, 2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 studyJosep Tabernero, Takayuki Yoshino, Allen Lee Cohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2025
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 StudyKohei Shitara, Sun Young Rha, Lucjan Wyrwicz, et al.
European Journal of Cancer (Oxford, England : 1990)|February 12, 2019
Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trialGianluca Masi, Caterina Vivaldi, Lorenzo Fornaro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2025
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized TrialsMarco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto, et al.
Targeted Oncology|May 10, 2021
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line TreatmentPina Ziranu, Eleonora Lai, Marta Schirripa, et al.
ESMO Open|April 10, 2019
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept studyChiara Cremolini, Matteo Benelli, Elisa Fontana, et al.
Frontiers in Oncology|February 26, 2024
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trialMarco Maria Germani, Guglielmo Vetere, Mirella Giordano, et al.
Annals of Surgical Oncology|May 5, 2025
Prognostic Value of Tumor Regression Grade After Chemotherapy Versus Chemoradiotherapy in Patients Undergoing Neoadjuvant Treatment for Locally Advanced Esophageal AdenocarcinomaGiovanni Capovilla, Elisa Sefora Pierobon, Lucia Moletta, et al.
Pageof 44